Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Interferon-based regimens and stem cell transplantations are the standard therapeutic options, with stem cell transplantation being the only curative therapy. As therapy for CML improves, molecular methods of monitoring response will become integrated in patient treatment. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as targeted therapy that offers new hope for expanded treatment options for patients with CML. Curr Opin Oncol 2001, 13:3-7 
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder resulting from the clonal expansion of a transformed hematopoietic stem cell. The progression of CML occurs in discrete phases. Following an initial chronic phase, lasting a median of 4 to 5 years, CML progresses to an accelerated phase of variable duration that heralds transition to a terminal acute leukemia called blast crisis. CML was the first malignancy in which a specific cytogenetic abnormality, the Philadelphia (Ph) chromosome, was clearly linked to disease pathogenesis. The understanding of the molecular pathogenesis of CML has allowed the development of specific molecularly targeted therapy, along with more accurate methods of monitoring disease. This article will focus on recent advances in these areas.
Clinical features and findings
Chronic myelogenous leukemia accounts for approximately one fifth of all leukemias, with an annual incidence of 1.5 cases per 100,000. It is generally a disease of older adults, with a median age of 50 years at presentation; however, all age groups are affected, including children. One quarter of patients are 60 years or older at diagnosis; this factor affects therapeutic strategies, such as stem cell transplantation. Most patients are diagnosed in the chronic phase of the illness, and one third or more of cases are detected by routine blood testing. Common presenting features include fatigue, weight loss, left upper-quadrant pain or abdominal fullness, early satiety, night sweats, and low-grade fevers. Peripheral blood counts in chronic phase CML reveal leukocytosis of variable degree with a majority of patients having white blood cell counts greater than 100,000/mm 3 at diagnosis. Anemia is often present in proportion to the degree of leukocytosis, and elevated platelet counts are found in approximately half of all patients. The peripheral blood smear in chronic phase CML contains a full spectrum of maturing myeloid elements ranging from blasts to neutrophils, the majority of forms being more mature, with less than 5% blasts. Basophilia is a hallmark feature of the peripheral blood and bone marrow, and eosinophilia is common. Morphologically, the bone marrow shows marked hypercellularity with myeloid hyperplasia; fibrosis and dysplasia are associated with disease progression.
Molecular pathogenesis
The majority of patients with chronic myelogenous leukemia have evidence of the Ph chromosome. As highlighted in a recent review [1•], it was initially described in 1960 as a shortened chromosome 22 [2] and subsequently identified as a (9:22) translocation [3] . This translocation juxtaposes sequences from the breakpoint cluster region (Bcr) on chromosome 22 with the cabl nonreceptor tyrosine kinase on the long arm of chromosome 9 [4], creating a bcr-abl fusion gene and protein.
A small minority of cases result from alternative or complex translocations, leading to a detectable fusion gene product but no evidence of the Ph chromosome via conventional cytogenetic analysis. Fewer than 5% of patients with clinical features of CML are Ph negative and bcr-abl negative. The clinical course of this small subset of patients differs from classical CML and is beyond the scope of this review.
Depending on the breakpoint in Bcr, the fusion gene commonly produces proteins of either 210 kD or 185 kD. In 95% of patients with CML, p210 bcr-abl is seen. In adults with acute lymphoblastic leukemia (ALL), 15 to 30% of these adults are Ph-chromosome positive; half are p210 positive, whereas the other half carries the p185 product. In childhood ALL, only 5% of patients are Ph positive; however, 80% of patients carry the p185 fusion protein. Additionally, a rare larger fusion protein that stems from splicing at a downstream Bcr locus, called p230, is associated clinically with the chronic neutrophilic leukemia variant and thrombocytosis.
Bcr-abl chimeric fusion protein products are constitutively activated tyrosine kinases with severalfold increased activity compared to c-abl [5] . Kinase activity is required for transforming activity of the bcr-abl protein [6, 7] . Evidence that bcr-abl causes malignant transformation has been demonstrated in experiments in which the introduction of bcr-abl alone causes leukemia in mice [8-10].
Management options for chronic myelogenous leukemia
A recent review [11••] took opinions from an expert panel to determine treatment recommendations for patients with CML. Using an overview-and evidencebased approach, updated guidelines for management of CML were reported. Given the results of several randomized trials and a recent meta-analysis [12], recombinant INF (interferon)-α emerged as first-line therapy for good prognosis, early chronic phase CML patients. INF-α can improve survival by an average of 20 months, but it is associated with well-described toxicity. The most substantial survival advantage occurs in patients with major cytogenetic responses to interferon therapy; however, there is evidence that hematologic response alone while on interferon may also offer measurable survival benefit [13] . Balancing the toxicity of interferon with the fact that substantial cytogenetic responses can occur 12 months into therapy and beyond, a reasonable trial of interferon at maximally tolerated doses is recommended for up to 1 year. Those patients identified as responding to therapy should continue on interferon; for patients without a cytogenetic response at 1 year, there may be little benefit in continuing interferon-based therapy because other management options could offer hematologic control with less toxicity.
Additional randomized data from the French CML Study Group [14] led to the recommendation to consider the addition of intermittent low-dose cytarabine (ara-C) to rINF-α to further increase survival, at the cost of additional toxicity. Although this analysis did not determine an optimal duration of such therapy, it stressed the importance of cytogenetic response as a correlate with increased survival in CML. Because this review focused on randomized trials, a clear evidencebased advantage was not evident for allogeneic stem cell transplantation. However, a large body of data [15, 16] supports the curative potential of allogeneic stem cell transplantation for CML, with an overall survival of up to 65% for human leukocyte antigen (HLA)-matched sibling donor transplantations. Recent results in selected well-matched younger patients have yielded similar results with unrelated donor transplantations [17•]. Regarding pretransplantation therapy, there has been some concern that prior therapy with interferon may adversely affect the outcome of transplantation. However, a recent report [18] suggests that if interferon is discontinued at least 90 days prior to transplantation, it does not adversely affect outcome.
The dilemma for physicians managing CML is to assist patients in deciding among the various management
The Bcr-Abl tyrosine kinase is a constitutively active kinase that functions by binding ATP and transferring phosphate from ATP to tyrosine residues on various substrates. This activity causes the excess proliferation of myeloid cells characteristic of CML. STI571 functions by blocking the binding of ATP to the Bcr-Abl tyrosine kinase, thus inhibiting the activity of the kinase. In the absence of tyrosine kinase activity, substrates required for Bcr-Abl function cannot be phosphorylated. A current focus of research in stem cell transplantation for CML is to improve outcome by decreasing early treatment-associated mortality while preserving relapsefree survival benefit. Several recent reports [22•-24•] have shown that the use of peripheral blood as a source of stem cells for transplantation yields a more rapid neutrophil and platelet recovery, without increasing acute graft-versus-host disease. Although too early to be conclusive, these reports also suggest that relapses are decreased. For patients who relapse after allogeneic stem cell transplantation, donor lymphocyte infusions have become the treatment of choice [25] . In an attempt to harvest this graft-versus-leukemia effect while minimizing the toxicity of conditioning regiments, a variety of nonmyeloablative stem cell transplantation procedures are being investigated as up-front therapy [26•]. Preliminary results confirm a decrease in early mortality; however, additional follow-up evaluation is necessary to assess leukemia-free survival. Nevertheless, this procedure allows for the ability to extend stem cell transplantation as a treatment option for older individuals.
STI571: rational development of a specific tyrosine kinase inhibitor
Given the understanding of CML at the molecular level and knowledge that the tyrosine kinase activity of the bcrabl gene product is essential to disease induction, development of an abl-specific kinase inhibitor was a rational therapeutic approach for CML [27••] . STI571 (formerly CGP57148), originally developed as a specific platelet derived growth factor-receptor (PDGF-R) inhibitor, was found to be a selective and potent inhibitor of the bcr-abl tyrosine kinase. It inhibits all the abl tyrosine kinases in vitro, and except for the PDGF-R and c-Kit tyrosine kinases, no others are affected [27••] . Preclinical studies revealed that STI571 specifically inhibited the proliferation of bcr-abl-expressing cells in vitro and in vivo [28] [29] [30] .
Given its favorable preclinical profile, phase I trials with STI571 began in June 1998. The initial trial, designed to find the maximally tolerated dose with a secondary endpoint of clinical benefit, included patients with chronic phase CML who had failed therapy with inter-feron. STI571 was given as daily oral therapy and has been well tolerated with no dose-limiting toxicity encountered. Hematologic responses were seen at dosages of 140 mg and more, and remarkably, 31 of 31 patients treated with 300 mg or more for at least 4 weeks showed complete hematologic responses [31••]. Responses were typically seen between 2 and 4 weeks of therapy and have been maintained beyond 8 months. At doses of 300 mg and more, cytogenetic responses were achieved in 45% of patients, with 10% achieving a complete cytogenetic response.
Based on safety and efficacy in interferon-refractory chronic phase patients, the phase I study was expanded to include patients with myeloid and lymphoid blast crisis of CML and relapsed or refractory Ph-positive ALL. Doses of 300 to 800 mg/d of STI571 were well tolerated in these patients. Response rates in all of these Ph chromosomepositive acute leukemia patients have been high (approaching 70%), particularly in comparison to historical controls. However, relapses have occurred in the majority of patients; only 18% of patients in myeloid blast crisis have remissions sustained beyond 6 months [32••].
Phase II trials using STI571 are ongoing in order to provide further data on efficacy and safety in larger numbers of patients. Additionally, a phase III randomized comparison of the combination of interferon and ara-c versus STI571 in newly diagnosed patients will assist in determining the role of STI571 as a standard management option for CML patients. Lastly, preclinical data demonstrates that the addition of STI571 to a variety of antileukemic agents has an enhanced antiproliferative effect [33•]. Thus, a combination of STI571 with standard antileukemic agents may be useful in improving the durability of responses seen in patients with blast crisis of CML. However, the ultimate goal of combination therapy would be to further improve the rate and durability of complete cytogenetic responses in patients with chronic phase CML.
The success of STI571 has caused substantial debate on how best to integrate such therapy into current treatment algorithms. Newly diagnosed patients without a transplantation option should be encouraged to participate in a multicenter clinical trial comparing STI571 to standard therapy with interferon and ara-C. For patients trying to decide between allogeneic stem cell transplantation versus opting to wait for availability of STI571, algorithms such as those used to decide between interferon and allogeneic transplantation should be incorporated with careful assessment of prognostic factors and therapeutic risks. Despite the curative potential of allogeneic stem cell transplantation, the emergence of more favorable nontransplantation therapies may make physicians and patients less willing to accept the risks of transplantation. Data emerging from ongoing clini-cal trials should further clarify the role of STI571 as an alternative to allogeneic stem cell transplantation.
Monitoring therapeutic efficacy in patients with chronic myelogenous leukemia
To accurately assess and differentiate response to various therapeutic interventions in patients with CML, predict which patients will relapse, and allow for early intervention, highly accurate and quantitative methods using reverse transcriptase polymerase chain reaction (RT-PCR) are available to detect levels of bcr-abl transcripts. After allogeneic stem cell transplantation, increasing levels of bcr-abl clearly predict relapse [34] . However, persistence of bcr-abl does not necessarily predict relapse, provided that transcripts remain below a threshold level. In patients treated with INF-α, only a minority of patients achieves a complete cytogenetic remission; in these patients, bcr-abl transcript levels also may predict relapse. Unfortunately, only a minority of these responding patients achieve bcr-abl transcript levels comparable to those of allogeneic stem cell transplantation recipients and compatible with a low risk of relapse [35,36•,37-39•] . As additional therapies improve the rate of complete cytogenetic response, molecular monitoring is likely to become increasingly important in the management of patients with CML. Furthermore, as the ability to intervene with new therapeutic approaches improves, the benefits of molecular monitoring may translate into improved therapeutic outcomes.
Conclusions and future directions
Developments in the treatment and monitoring of therapeutic response in patients with chronic myelogenous leukemia during the past few decades herald the dawn of a new era in the management of malignancies. Beginning with recognition of the Ph chromosome, understanding of the molecular pathogenesis of CML has allowed for the application of molecular monitoring of the disease and has led to the development of a rationally designed, molecularly targeted therapeutic agent with remarkable efficacy. As the understanding of other malignancies advances to the molecular level, it will assuredly improve preclinical diagnostic capabilities, foster the development of a variety of novel and targeted therapies, and allow for advances in detection of minimal residual disease.
